PARD (Poniard Pharmaceuticals) Research & Development: $1.17 Mil (TTM As of Sep. 2011)


What is Poniard Pharmaceuticals Research & Development?

Poniard Pharmaceuticals PARD Research & Development is $1.17 Mil as of Sep. 2011.

Research & Development is the aggregate amount of research and development expenses during the year. Poniard Pharmaceuticals's Research & Development for the three months ended in Sep. 2011 was $0.29 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2011 was $1.17 Mil.

Poniard Pharmaceuticals  (OTCPK:PARD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Poniard Pharmaceuticals Research & Development Related Terms

Poniard Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Research & Development Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.36 23.37 33.73 25.74 7.98

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.11 0.33 0.44 0.29

Poniard Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.17 Mil mean?
Poniard Pharmaceuticals (PARD) has a Research & Development of $1.17 Mil as of Sep. 2011. Research and development expense is the total cost for research and development activities. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Research & Development too high?
Poniard Pharmaceuticals' current Research & Development is $1.17 Mil.
How does Poniard Pharmaceuticals' Research & Development compare to OBMP and NSPX?
Poniard Pharmaceuticals' Research & Development of $1.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Research & Development is $1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Research & Development of $1.17 Mil. The current Research & Development is $1.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Research & Development is $1.17 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.